Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated ...

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT ...

The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.

The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.